Global Parathyroid Hormone Market Size By Type (Hypocalcemia, Hypoparathyroidism), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Parathyroid Hormone Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 4.6 billion by 2031, growing at a CAGR of 10.1% from 2023 to 2031. Parathyroid hormone (PTH) therapies, including both synthetic and recombinant versions, are primarily used in the treatment of osteoporosis, hypoparathyroidism, and other calcium imbalance-related disorders. The rising prevalence of osteoporosis, growing awareness of rare endocrine disorders, and advancements in biologics and hormone replacement therapies are key factors propelling the market forward.

Drivers:

Rising Incidence of Osteoporosis and Bone Disorders:

Globally, the increasing aging population is leading to a surge in osteoporosis and calcium deficiency disorders, driving demand for PTH-based treatments. Postmenopausal women and elderly men form a substantial part of the patient base benefiting from PTH therapy.

Advancements in Hormonal Therapies:

Progress in biotechnology has paved the way for more effective and targeted parathyroid hormone analogs. These innovations enhance therapeutic outcomes and reduce side effects, supporting stronger market adoption.

Regulatory Approvals and Pipeline Expansion:

A growing number of drugs under clinical trials and favorable regulatory environments in developed markets like the U.S. and EU are driving the entry of new PTH-based treatments, widening patient access.

Restraints:

High Treatment Costs:

Parathyroid hormone therapies, particularly biologics, come with significant costs, limiting their affordability in developing economies. Lack of comprehensive reimbursement policies in several regions further dampens market expansion.

Limited Awareness and Diagnosis:

Many individuals with parathyroid dysfunction or early-stage osteoporosis remain undiagnosed due to lack of routine screening, particularly in rural and underdeveloped regions, hampering potential market reach.

Opportunity:

Emerging Markets Expansion:

Asia-Pacific and Latin America are expected to offer high growth potential due to improving healthcare infrastructure, increasing diagnosis rates, and growing awareness regarding bone health and endocrine disorders.

Combination Therapies and Novel Drug Delivery:

Development of combination treatments that use PTH analogs with anti-resorptive agents, as well as new drug delivery systems like nasal sprays or long-acting injectables, present lucrative opportunities for innovation and differentiation.

Market by System Type Insights:

By product type, the Teriparatide segment dominated the market in 2023, attributed to its widespread use in treating severe osteoporosis in postmenopausal women. Teriparatide has established clinical efficacy and remains a first-line choice in hormone therapy.

Meanwhile, the Recombinant Human Parathyroid Hormone (rhPTH 1-84) segment is expected to witness the fastest growth through 2031 due to its specific use in hypoparathyroidism and recent global regulatory approvals.

Market by End-use Insights:

The Hospitals segment accounted for the largest revenue share in 2023, driven by a high volume of hormone therapy administrations and specialized care. With advanced diagnostics and endocrinology departments, hospitals remain the primary treatment setting.

The Specialty Clinics segment is anticipated to expand rapidly as more clinics adopt hormone therapy protocols, especially for osteoporosis and rare endocrine disorders, offering convenience and outpatient care services.

Market by Regional Insights:

North America led the global market in 2023, owing to high diagnosis rates, established healthcare systems, and the early adoption of innovative biologic treatments. The U.S. remains a dominant contributor, supported by favorable insurance coverage and active clinical research.

Asia-Pacific is forecasted to witness the fastest growth during the forecast period, driven by increasing healthcare spending, improving public awareness, and expanding pharmaceutical access in China, India, and Southeast Asia.

Competitive Scenario:

Key companies operating in the Global Parathyroid Hormone Market include Eli Lilly and Company, Shire (now part of Takeda Pharmaceutical Company Limited), Ascendis Pharma, Entera Bio, Radius Health, and Pfizer Inc. These firms are focusing on product innovations, clinical trials, and strategic alliances to expand their market presence. For instance:

In 2023, Radius Health received extended approval for the use of its teriparatide biosimilar in the EU and Asia.

Ascendis Pharma advanced its long-acting PTH formulation into Phase III trials, targeting once-weekly dosing convenience.

Entera Bio reported promising Phase II results for its oral PTH treatment for osteoporosis, potentially disrupting the injectable market.

Scope of Work – Global Parathyroid Hormone Market

Report Metric Details

Market Size (2023) USD 2.1 Billion

Projected Market Size (2031) USD 4.6 Billion

CAGR (2023–2031) 10.1%

Market Segments By Product Type (Teriparatide, rhPTH 1-84), End-use (Hospitals, Specialty Clinics), Region

Growth Drivers Rising incidence of osteoporosis, advancements in hormone therapies, regulatory approvals

Opportunities Emerging market penetration, novel delivery systems, combination therapies

Key Market Developments:

January 2023: Entera Bio initiated Phase III trials for oral PTH therapy, targeting both osteoporosis and hypoparathyroidism.

June 2023: FDA approved Takeda’s extended-release PTH formulation for hypoparathyroidism.

September 2024: Eli Lilly announced R&D investments exceeding USD 500 million for expanding its endocrine disorder pipeline.

FAQs:

1) What is the current market size of the Global Parathyroid Hormone Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Parathyroid Hormone Market?

The key driver is the rising prevalence of osteoporosis and advancements in hormone-based therapies.

3) Which is the largest region during the forecast period in the Global Parathyroid Hormone Market?

North America is the largest region, owing to high healthcare spending and rapid adoption of biologics.

4) Which segment accounted for the largest market share in the Global Parathyroid Hormone Market?

The Teriparatide segment held the largest market share in 2023.

5) Who are the key market players in the Global Parathyroid Hormone Market?

Major players include Eli Lilly, Shire (Takeda), Radius Health, Ascendis Pharma, and Entera Bio.

Let me know if you’d like this exported as a document or added into a report layout!